GlassScriptPhysician profile
Samer Hassan
NPI 1033421284
$1,545.89
in general payments reported to CMS, 2019-2025
30 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $43.63 · 2021: $35.85 · 2022: $233 · 2023: $526 · 2024: $235 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.36 |
| Education | $177.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $211.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $182.31 | 2019-2025 | |
| Lilly USA, LLC | $150.25 | 2019-2023 | Jaypirca, Retevmo, Verzenio |
| Abbvie INC. | $89.54 | 2019-2025 | |
| Genzyme Corporation | $84.04 | 2019-2024 | |
| Gilead Sciences, INC. | $81.02 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $76.42 | 2019-2023 | Keytruda, Lynparza |
| Genentech USA, INC. | $71.51 | 2020-2025 | Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $64.29 | 2019-2025 | Enhertu, Imfinzi |
| Celgene Corporation | $53.88 | 2023 | Reblozyl, Opdualag |
| Sumitomo Pharma America, INC. | $47.86 | 2023 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $35.26 | 2023-2024 | Opdivo |
| Incyte Corporation | $32.49 | 2023 | Jakafi, Pemazyre, Monjuvi |
| Ipsen Biopharmaceuticals, INC | $32.46 | 2024 | Onivyde, Tazverik |
| Daiichi Sankyo INC. | $29.71 | 2025 | Enhertu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $26.11 | 2025 | Mektovi, Braftovi, Xalkori |
| Beigene USA, INC. | $25.37 | 2023 | Brukinsa |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.82 | 2019 | |
| Astellas Pharma US INC | $22.65 | 2023 | Padcev |
| Eisai INC. | $21.74 | 2023 | |
| Seagen INC. | $20.19 | 2023 | Tukysa |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.79 | 2022 | |
| Exelixis INC. | $19.39 | 2025 | Cabometyx |
| Janssen Biotech, INC. | $19.28 | 2023 | Darzalex |
| Geron Corporation | $17.89 | 2025 | Rytelo |
| Sobi, INC | $16.86 | 2024 | |
| Amgen INC. | $14.34 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.